NCT04551911View on ClinicalTrials.gov

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

October 8, 2021

Study Completion Date

October 8, 2021

Conditions
COVID-19CoronavirusSARS-CoV2 Infection
Interventions
DRUG

Rayaldee

30 mcg calcifediol Extended-Release (ER) Capsule

DRUG

Placebo

0 mcg calcifediol Extended-Release (ER) Capsule

Trial Locations (10)

20723

OPKO Investigative Site, Laurel

33173

OPKO Investigative Site, Miami

33185

OPKO Investigative Site, Miami

39601

OPKO Investigative Site, Brookhaven

48312

OPKO Investigative Site, Sterling Heights

48334

OPKO Investigative Site, Farmington Hills

49201

OPKO Investigative Site, Jackson

60201

OPKO Investigative Site, Evanston

68131

OPKO Investigative Site, Omaha

94127

OPKO Investigative Site, San Francisco

All Listed Sponsors
lead

OPKO Health, Inc.

INDUSTRY

NCT04551911 - Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 | Biotech Hunter | Biotech Hunter